Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Vyne Therapeutics Inc (VYNE)

Vyne Therapeutics Inc (VYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,817
  • Shares Outstanding, K 58,036
  • Annual Sales, $ 14,760 K
  • Annual Income, $ -73,330 K
  • 60-Month Beta 1.53
  • Price/Sales 0.99
  • Price/Cash Flow N/A
  • Price/Book 0.37
Trade VYNE with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.68
  • Most Recent Earnings -0.16 on 11/10/22
  • Next Earnings Date 03/16/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 419.65% ( -500.76%)
  • Historical Volatility 247.35%
  • IV Percentile 83%
  • IV Rank 30.76%
  • IV High 1,208.37% on 11/18/22
  • IV Low 69.32% on 02/17/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 25
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 266
  • Open Int (30-Day) 524

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.18
  • Number of Estimates 1
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1405 +81.71%
on 01/04/23
0.3823 -33.22%
on 01/10/23
+0.1178 (+85.67%)
since 01/03/23
3-Month
0.1107 +130.62%
on 12/23/22
0.3823 -33.22%
on 01/10/23
-0.0176 (-6.45%)
since 11/03/22
52-Week
0.1107 +130.62%
on 12/23/22
0.7900 -67.68%
on 04/01/22
-0.3079 (-54.67%)
since 02/03/22

Most Recent Stories

More News
Pre-Market Brief: Stocks Mostly Lower As Hawkish Fed Remarks Weigh On Sentiment, Powell Speech In Focus

March S&P 500 futures (ESH23) are trending down -0.08% this morning after three major U.S. benchmark indices ended the regular session mixed following hawkish remarks from two U.S. Federal Reserve officials,...

ESH23 : 4,147.75s (-1.04%)
AAPL : 154.50 (+2.44%)
GOOGL : 104.78 (-2.75%)
MSFT : 258.35 (-2.36%)
NVDA : 211.00 (-2.81%)
OSH : 26.62 (-2.78%)
VYNE : 0.2553 (-1.43%)
FRO : 14.58 (+0.41%)
BLI : 2.43 (+2.97%)
WWW : 16.21 (-1.16%)
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0% and 67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

VYNE : 0.2553 (-1.43%)
MDWD : 13.90 (-0.79%)
All You Need to Know About VYNE Therapeutics Inc. (VYNE) Rating Upgrade to Buy

VYNE Therapeutics Inc. (VYNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

VYNE : 0.2553 (-1.43%)
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Misses Revenue Estimates

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 13.33% and 58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

VYNE : 0.2553 (-1.43%)
LJPC : 6.22 (unch)
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 0.2553 (-1.43%)
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 17.65% and 7.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CPRX : 16.10 (+1.90%)
VYNE : 0.2553 (-1.43%)
VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference

BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 0.2553 (-1.43%)
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

Top-line Efficacy Results Expected in Approximately 6 to 8 Weeks...

VYNE : 0.2553 (-1.43%)
VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference

BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 0.2553 (-1.43%)
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

VYNE : 0.2553 (-1.43%)
HQY : 60.04 (+1.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

VYNE Therapeutics Inc. focuses on developing and commercializing therapeutics for dermatology. The company's product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo Therapeutics Inc., is based in Bridgewater, New Jersey.

See More

Key Turning Points

3rd Resistance Point 0.2814
2nd Resistance Point 0.2757
1st Resistance Point 0.2655
Last Price 0.2553
1st Support Level 0.2496
2nd Support Level 0.2439
3rd Support Level 0.2337

See More

52-Week High 0.7900
Fibonacci 61.8% 0.5305
Fibonacci 50% 0.4504
Fibonacci 38.2% 0.3702
Last Price 0.2553
52-Week Low 0.1107

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar